Effect of CGP57148B on ara-C– or doxorubicin-induced apoptosis of HL-60/neo, HL-60/Bcr-Abl, and K562 cells
| . | % apoptotic cells . | |||
|---|---|---|---|---|
| HL60/Bcr-Abl . | K562 . | |||
| Annexin V . | Sub-G1 phase . | Annexin V . | Morphology . | |
| Control | 4.0 ± 1.7 | 6.3 ± 2.0 | 2.6 ± 0.7 | 3.6 ± 4.7 |
| CGP | 14.8 ± 2.5 | 14.1 ± 1.6 | 18.3 ± 2.4 | 15.1 ± 1.6 |
| Ara-C | 11.9 ± 3.0 | 11.6 ± 1.3 | 14.5 ± 2.5 | 15.1 ± 1.5 |
| CGP + Ara-C | 25.4 ± 3.3* | 36.8 ± 1.1* | 28.8 ± 1.8* | 35.0 ± 0.3* |
| Dox | ND | 33.6 ± 0.2 | ND | 27.1 ± 2.0 |
| CGP + Dox | ND | 64.4 ± 1.1* | ND | 40.1 ± 1.6* |
| . | % apoptotic cells . | |||
|---|---|---|---|---|
| HL60/Bcr-Abl . | K562 . | |||
| Annexin V . | Sub-G1 phase . | Annexin V . | Morphology . | |
| Control | 4.0 ± 1.7 | 6.3 ± 2.0 | 2.6 ± 0.7 | 3.6 ± 4.7 |
| CGP | 14.8 ± 2.5 | 14.1 ± 1.6 | 18.3 ± 2.4 | 15.1 ± 1.6 |
| Ara-C | 11.9 ± 3.0 | 11.6 ± 1.3 | 14.5 ± 2.5 | 15.1 ± 1.5 |
| CGP + Ara-C | 25.4 ± 3.3* | 36.8 ± 1.1* | 28.8 ± 1.8* | 35.0 ± 0.3* |
| Dox | ND | 33.6 ± 0.2 | ND | 27.1 ± 2.0 |
| CGP + Dox | ND | 64.4 ± 1.1* | ND | 40.1 ± 1.6* |
HL-60/Bcr-Abl and K562 cells were exposed to 0.25 μmol/L CGP57148B (CGP) and/or Ara-C (5 μmol/L) or doxorubicin (Dox) (0.25 μmol/L) for 48 hours. Following this, cells were harvested and percent apoptotic cells was determined by morphology and annexin V or PI staining followed by flow cytometry. Values represent mean ± SEM of 3 separate experiments.
ND indicates not done due to technical difficulties caused by doxorubicin fluorescence.
Values are significantly different from those cells treated with Ara-C or Dox alone (P < .05).